Cowen & Co. analyst Boris Peaker maintained a Hold rating on Ironwood Pharma (IRWD) today and set a price target of $12. The company’s shares closed yesterday at $10.27.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 3.2% and a 41.6% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Molecular Templates Inc, and CytomX Therapeutics Inc.
Ironwood Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $17.25.
See today’s analyst top recommended stocks >>
The company has a one-year high of $17.74 and a one-year low of $7.59. Currently, Ironwood Pharma has an average volume of 1.44M.
Based on the recent corporate insider activity of 73 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which engages in the discovery, commercialization, and development of medicines. Its products include linaclotide, a guanylate cyclase type-C agonist which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F.
